Dingdang Health Technology Group (SEHK:9886) Loss Narrows To C¥51.7m Challenging Bearish Narratives

Dingdang Health Technology Group (SEHK:9886) has posted its FY 2025 first half results with revenue of C¥2.3b, a basic EPS loss of C¥0.04 per share and net income loss of C¥51.7m, keeping the focus firmly on the path toward breakeven. Over the recent reporting periods, revenue has moved from C¥2.27b in 1H 2024 to C¥2.40b in 2H 2024 and C¥2.33b in 1H 2025, while basic EPS losses have shifted from C¥0.06 in 1H 2024 to C¥0.22 in 2H 2024 and C¥0.04 in 1H 2025. This sets up an earnings season where you are likely watching whether narrowing losses can eventually translate into more resilient margins.

See our full analysis for Dingdang Health Technology Group.

With the headline numbers on the table, the next step is to see how this earnings profile lines up with the most widely held narratives around Dingdang Health Technology Group and where those stories may need to be updated.

Curious how numbers become stories that shape markets? Explore Community Narratives

TTM loss of C¥343.7m keeps profitability in focus

• On a trailing 12 month basis, Dingdang Health reported revenue of C¥4.7b and a net loss of C¥343.7m, compared with a first half FY 2025 loss of C¥51.7m on C¥2.3b revenue. This means you are still looking at a business that is generating sizeable sales while remaining loss making over the full year window.
• What stands out for a cautious, more bearish view is that negative EPS of C¥0.26 over the trailing 12 months and C¥0.04 in the latest half both align with the concern that the business has not yet shown positive net income. At the same time, the data also notes that losses have been shrinking over a multi year period at an average rate of 33.6%, which partly softens that bearish angle.
  • Bears focus on the fact that every period in the table, including 1H 2024, 2H 2024, and 1H 2025, still shows a net loss in the tens or hundreds of millions of CNY. From this perspective, the path to sustained profit is not yet visible in the numbers provided.
  • At the same time, the reduction in trailing 12 month loss from C¥376.5m to C¥343.7m means critics need to grapple with a data set that shows ongoing losses but also measurable progress in reducing them. This complicates a simple negative story.

Sequential loss reduction from C¥292.0m to C¥51.7m

• Looking at the last three half years, net loss moved from C¥84.5m in 1H 2024 to C¥292.0m in 2H 2024 and then narrowed to C¥51.7m in 1H 2025, while revenue stayed in a relatively tight band between C¥2.27b and C¥2.40b. This shows the company handling roughly similar revenue levels with very different loss sizes across periods.
• Supporters with a more bullish tilt point to the combination of C¥4.7b trailing 12 month revenue and a smaller recent half year loss of C¥51.7m as evidence that the business model can move closer to breakeven. Yet those same figures also remind you that the trailing picture of a C¥343.7m loss is still large, so the bullish case rests on the idea that this pattern of smaller recent losses can persist.
  • The data that losses have been narrowing at an average rate of 33.6% per year over five years sits alongside the latest basic EPS figures of C¥0.06 loss in 1H 2024, C¥0.22 loss in 2H 2024, and C¥0.04 loss in 1H 2025. Together, these give bulls concrete numbers to point to when they argue that the earnings profile is moving in the right direction.
  • However, because every EPS figure in the table is still negative, anyone leaning bullish has to accept that the story is about loss reduction rather than proven profitability. The financials both support optimism about operational improvement and underline that the turnaround is not yet complete.

P/S of 0.2x versus peers at 1.4x

• On valuation, the current share price of HK$0.82 implies a P/S of 0.2x compared with 1.4x for peers and 0.6x for the wider Hong Kong consumer retail industry. The stock also sits below a stated DCF fair value of HK$2.02, which together point to a large gap between these reference points and the current market level.
• Supportive, more bullish commentary leans heavily on this gap, arguing that trading about 59.4% below the DCF fair value and at a fraction of peer and industry P/S multiples could reflect under appreciation of a business that produced C¥4.7b of trailing 12 month revenue. Yet the same figures also make clear that any interpretation of value has to be weighed against the fact that this revenue base is paired with a C¥343.7m trailing 12 month loss.
  • Backers of the bullish angle highlight that a low P/S ratio of 0.2x is being applied to a company that has reduced its trailing 12 month loss from C¥376.5m to C¥343.7m. From that perspective, the valuation metrics are being read together with the multi year trend of shrinking losses rather than in isolation.
  • Others may look at the same numbers and conclude that the discount relative to the HK$2.02 DCF fair value and to peer P/S simply lines up with the ongoing unprofitability. This shows how the valuation figures do not settle the bullish debate but instead frame how much weight investors are putting on future progress toward breakeven.

If you want to see how other investors connect these valuation signals and loss trends into a single story, it is worth reading the community discussion around Dingdang Health Technology Group through the 📊 Read the what the Community is saying about Dingdang Health Technology Group.

Next Steps

Don't just look at this quarter; the real story is in the long-term trend. We've done an in-depth analysis on Dingdang Health Technology Group's growth and its valuation to see if today's price is a bargain. Add the company to your watchlist or portfolio now so you don't miss the next big move.

After weighing these mixed signals, the next step is to look at the numbers yourself, compare them with your expectations and decide how convincing the breakeven story feels. If you want a quick way to see what is getting investors optimistic, take a closer look at the 1 key reward.

See What Else Is Out There

Dingdang Health Technology Group is still posting sizeable losses, with C¥343.7m TTM loss and consistently negative EPS figures. Profitability and earnings stability therefore remain key concerns.

If that level of ongoing loss makes you want steadier prospects, you may wish to filter for companies with stronger fundamentals and financial resilience using the solid balance sheet and fundamentals stocks screener (382 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com